Resources

RISE study data on improvements of beta-cell function in type 2 diabetes found response to treatment differs in adults vs youth.

I am a retail pharmacist working in a busy chain pharmacy.  A patient came in and requested a temporary supply of his Crestor 40 mg tablets because he had run out of tablets before he was eligible for a refill through insurance.  I checked his profile and noticed that it had been 1 1/2 months since his last 90 day refill so I asked why he had run out.  He said that his doctor had told him to double up and take 80 mg daily.  This didn't sound correct, but it was after office hours and the patient was adamant that these were his doctor's instructions and that he would have to stop his medication if I didn't dispense to him. 

An updated consensus report from the American Diabetes Association has pushed focus towards nutrition therapy as a viable alternative to classic pharmacotherapy.

Why patients with type 1 diabetes are more likely to spend time in hypoglycemia.

Expansion of the original 2015 approval makes Praluent a strong lipid-lowering candidate for patients with diabetes and other cardiovascular concerns.

In this Exclusive Interview, Catherine L. Davis  talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the surprising results of a study on exercise dose in children with obesity.

In this Exclusive Interview transcript, Catherine L. Davis  talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the surprising results of a study on exercise dose and obesity in children.

In this Exclusive Interview, Kevin Sayer  talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the Dexcom G6 CGM System and how the future of CGM will affect the way not only type 1, but also type 2 and prediabetes are treated.

In this Exclusive Interview transcript, Kevin Sayer  talks with Diabetes in Control Publisher Steve Freed  about the Dexcom G6 CGM System and the future of CGMs changing diabetes management for type 1, type 2, and even prediabetes. Click here to view the video interview. Steve Freed: This is Steve Freed …

In this Exclusive Interview, Lora K. Heisler talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about harnessing serotonin in the treatment of obesity and type 2 diabetes.